We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sends Complete Response for Transcept’s Intermezzo
FDA Sends Complete Response for Transcept’s Intermezzo
November 6, 2009
The FDA has requested more safety data on Transcept Pharmaceuticals’ insomnia drug Intermezzo in a complete response letter that the company says will require one or more additional clinical trials.